Exelixis Inc. (EXEL)
EXEL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-01-02, https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/0000939767-26-000021-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-01-02.
Profile
| Field | Value |
|---|---|
| Ticker | EXEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0000939767 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.3B |
| Net income | $782.6M |
| Operating income | $872.2M |
| Net margin | 33.7% |
| Operating margin | 37.6% |
| Revenue growth | +7.0% |
| Cash | $482.5M |
| Total assets | $2.8B |
| P/E (computed) | 20.9× |
| P/S (computed) | 7.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $304.8M cash; operating cash flow $293.3M a quarter. | Report 2026-10-02 |
| Shares outstanding | 244,010,895 (2026-10-19); 268,112,157 a year earlier; 310,974,113 three years earlier. | Cover page 2026-10-19 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-02-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.2M, sold $42.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-10-02 | $658.7M | $218.1M | $280.0M | $304.8M | No debt tags | $2.5B | 10-Q 2026-10-29 |
| Q2 2026 2026-07-03 | $628.7M | $212.1M | $307.7M | $281.4M | No debt tags | $2.4B | 10-Q 2026-08-05 |
| Q1 2026 2026-04-03 | $610.8M | $210.5M | $251.8M | $226.2M | No debt tags | $2.4B | 10-Q 2026-05-05 |
| Q4 2025 2026-01-02 | $598.7M | $244.5M | $333.5M | $482.5M | No debt tags | $2.3B | 10-K 2026-02-10 |
| Q3 2025 2025-10-03 | $597.8M | $193.6M | $290.3M | $376.3M | No debt tags | $2.3B | 10-Q 2026-10-29 |
| Q2 2025 2025-07-04 | $568.3M | $184.8M | $49.0M | $164.4M | No debt tags | $2.2B | 10-Q 2026-08-05 |
| Q1 2025 2025-04-04 | $555.4M | $159.6M | $211.4M | $183.8M | No debt tags | $2.3B | 10-Q 2026-05-05 |
| Q4 2024 2025-01-03 | $566.8M | $139.9M | $240.3M | $217.4M | No debt tags | $2.2B | 10-K 2026-02-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-10 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.8% |
| 1 month | +15.9% |
| 3 months | +36.3% |
| Year to date | +57.4% |
| 1 year | +62.9% |
| From 52-week high | -5.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier